Mephedrone
4-methylmethcathinone
Viewing r1 — Apr 20, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Mephedrone (4-methylmethcathinone) — meow meow, meph, M-CAT — is a synthetic stimulant-empathogen of the substituted cathinone class. It is structurally related to both amphetamine and MDMA, distinguished by its β-keto group. Mephedrone is a non-selective monoamine releasing agent, producing its effects by driving simultaneous release of dopamine, norepinephrine, and serotonin.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
MDMA, amphetamine, methamphetamine +2 moreMDMA, amphetamine, methamphetamine, methylone, cocaine show less
First synthesized in 1929 by Saem de Burnaga Sanchez,[3] mephedrone was forgotten for over seven decades before anonymous rediscovery in 2003 and rapid commercial emergence. By 2009 it had become one of the most popular recreational drugs in the United Kingdom,[4] sold openly online as "plant food" and "bath salts." Classified as a controlled substance across all major Western jurisdictions by 2012,[5] it remains in global circulation, notably within chemsex communities.[6]
Subjective effects include euphoria, empathy enhancement, emotional warmth, tactile enhancement, thought acceleration, and wakefulness. The experience sits between amphetamine and MDMA — stimulant energy and entactogenic warmth converging in a combination that neither compound alone replicates, shaped by an unusually fast onset and short duration. Compulsive redosing driven by the rapid offset, bruxism, anxiety on the comedown, and difficulty sleeping are characteristic unsought effects.
Mephedrone carries notable abuse liability from compulsive redosing,[7] with cardiovascular toxicity[8] and serotonin syndrome[9] as primary acute risks. Its short half-life[10] drives rapid dopamine surges and crashes that sustain binge patterns; in animals, binges produce persistent serotonin deficits paralleling MDMA.[11] Two controlled human trials[12][13] and extensive preclinical work make it among the better-characterized novel psychoactive substances, though human neurotoxicity data remain absent.
History[edit]
Discovery
Mephedrone was first synthesized in 1929 by Saem de Burnaga Sanchez, who published the preparation in the Bulletin de la Société Chimique de France.[3] No psychoactive properties were investigated; the compound sat untouched for over seventy years. In 2003, an anonymous chemist using the pseudonym "Kinetic" published the synthesis on The Hive, an early online forum for recreational drug chemistry — constituting the first modern publication of its preparation.[3]
Market emergence and cultural impact
By 2007 mephedrone was commercially available through Israeli head shops and internet vendors. Between 2009 and 2010 it experienced explosive growth in the United Kingdom, marketed as "plant food" or "bath salts" to sidestep drug legislation, becoming one of the most popular recreational drugs in the country — particularly prevalent at festivals and nightclubs.[4] Israel enacted the first national ban in December 2007, followed by Denmark and Sweden in December 2008.
Prohibition and modern use
The United Kingdom classified mephedrone as a Class B substance in April 2010, the European Union adopted criminal measures later that year, and the United States placed it on Schedule I in 2012.[5] Despite near-universal prohibition, mephedrone remains in circulation globally — it was the most frequently detected novel psychoactive substance in UK forensic casework during 2010–2012[14] and has emerged as a key substance in chemsex-associated fatalities between 2017 and 2022.[6] Two Phase I clinical trials from Barcelona constitute the only controlled human pharmacological data.[12][13]
The name "mephedrone" blends "methyl," "ephedrone," and the cathinone suffix — a naming convention typical of novel psychoactive substance marketing. On UK streets during 2009–2010 it circulated under dozens of aliases: "meow meow," "meph," "M-CAT," "drone," and "bubbles" among the most common. The "plant food" and "bath salts" labels were legal fictions — packaging carried "not for human consumption" disclaimers to evade medicines regulation, a loophole that defined the first wave of novel psychoactive substance commerce.
Chemistry[edit]
Structural class
Mephedrone belongs to the substituted cathinone class — β-keto amphetamine derivatives in which the phenethylamine backbone carries a ketone group at the β-carbon. The parent compound is cathinone, the naturally occurring stimulant alkaloid in Catha edulis (khat). Mephedrone is specifically the 4-methyl, N-methyl structural analog of cathinone, making it the β-keto counterpart of 4-methylmethamphetamine.[1]
Its structural kinship with MDMA — both are ring-substituted, N-methylated phenethylamine derivatives — underlies their shared entactogenic pharmacology, though mephedrone carries a β-keto group where MDMA has a methylenedioxy ring.[1]
Molecular structure
| Molecular formula | C₁₁H₁₅NO |
| Molecular weight | 177.24 g/mol (free base); 213.70 g/mol (HCl salt) |
The molecule consists of a para-methylphenyl ring attached to a propan-1-one chain bearing both a β-keto group (the cathinone class marker) and an N-methylamino group on the α-carbon.[15]
Stereochemistry
Mephedrone has one chirality center at the α-carbon, producing R- and S-enantiomers. The commercially encountered substance is the racemic mixture. The R-enantiomer is primarily responsible for rewarding and reinforcing properties: in animal self-administration studies, R-mephedrone produced higher progressive ratio breakpoints and greater positive affect than S-mephedrone.[16]
Physical properties
The free base is a yellowish liquid at room temperature. The hydrochloride salt — the form most commonly encountered — is a white to off-white crystalline powder with high water solubility, enabling oral, intranasal, and intravenous administration.[15]
Pharmacology[edit]
Mechanism of action
Mephedrone is a non-selective monoamine releasing agent — it enters dopamine, norepinephrine, and serotonin transporters as a substrate and forces each neurotransmitter out of the nerve terminal into the synapse.[1][2] This mechanism is shared with MDMA and distinguishes substrate-type releasers from pure transporter blockers like MDPV.[17]
At human transporters, mephedrone releases serotonin with greater efficacy than dopamine — acting as a full releaser at the serotonin transporter but only a partial releaser at the DAT.[18] This asymmetry helps explain its entactogenic character.
Unlike classical amphetamines, mephedrone does not activate TAAR1 (TAAR1), removing a regulatory feedback pathway from its pharmacological profile.[2] It also exhibits high blood-brain barrier permeability, ranking among the highest of all tested synthetic cathinones.[2]
When the dopamine transporter is blocked (as by MDPV), mephedrone can still release monoamines through an alternative pathway via organic cation transporter 3 (OCT3)[19] — producing paradoxically potent effects during co-administration with transporter blockers. Cardiovascular effects are transporter-mediated rather than caused by direct action on heart ion channels.[8]
Pharmacokinetics
After oral dosing (150 mg), mephedrone reaches peak blood levels in about one hour, with an half-life of approximately 2.2 hours.[10] A head-to-head trial comparing 200 mg oral mephedrone to 100 mg MDMA confirmed the dramatically shorter duration: mephedrone peaked at 1.25 hours with a half-life of 2.15 hours, versus MDMA's peak at 2 hours and half-life of 7.89 hours.[12] Effects scale linearly with dose across the 50–200 mg oral range.[20]
Intranasal administration produces slightly faster absorption (peak at approximately 53 minutes) with a similar half-life of about 2 hours.[21] The intranasal route delivers higher bioavailability per milligram.[22]
The primary metabolic enzyme is CYP2D6.[23][20] The most abundant urinary metabolite is 4’-carboxy-mephedrone (approximately 10× the parent compound in urine), while N-succinyl-nor-mephedrone has the longest detection window at 8.2 hours.[24][21][23] Both mephedrone and its nor-mephedrone metabolite cross the blood-brain barrier.[24]
Neuroscience[edit]
Where it acts
Mephedrone powerfully activates the brain's reward circuitry. A single dose raises dopamine levels in the nucleus accumbens to nearly five times baseline, while serotonin surges to over nine times baseline — comparable to MDMA's serotonin release at equivalent doses.[25] The dopamine transients are large and fast (clearing in roughly 25 minutes), a temporal profile characteristic of highly reinforcing substances. Brain stimulation reward studies confirm dose-dependent potentiation of reward pathways.[26]
The serotonergic dominance underlies the entactogenic warmth that separates mephedrone from purely dopaminergic stimulants. Mephedrone's locomotor-activating effects depend on available serotonin stores, and vesicular monoamine reserves play a key role in the release mechanism.[27]
Why it matters
The stereoselective reinforcement data — the R-enantiomer driving higher motivation and greater positive affect than the S-enantiomer[16] — illuminates a dissociation between "wanting" (motivational drive) and "liking" (hedonic pleasure). The rapid-onset, rapid-offset dopamine profile[25] is precisely the temporal pattern predicted to maximize compulsive pursuit of the next dose.
Binge-pattern exposure in rats produces rapid decreases in SERT function in the hippocampus without dopaminergic damage[11] — paralleling MDMA's neurotoxicity profile rather than methamphetamine's. Repeated exposure also produces long-term changes in anxiety-related behavior and monoamine system markers,[28] with brain imaging revealing substance-specific neural remodeling distinct from methamphetamine.[29]
- Does mephedrone produce neurotoxicity in humans? All current evidence comes from animal models; no controlled human neuroimaging studies have been conducted.
- Why do rodents show hypothermia[30][31] while human overdose cases present with dangerous overheating? Ambient temperature is a critical modifier,[32] but the full mechanism in humans remains uncharacterized.
- Does the alternative release pathway via OCT3[19] operate at relevant concentrations in living humans?
Subjective Effects[edit]
Mephedrone occupies a distinctive experiential niche between amphetamine and MDMA — stimulant energy and entactogenic warmth converging without fully replicating either. Route of administration shapes the balance: oral dosing favors a more gradual arc with greater emotional warmth, while insufflation delivers a sharper, faster onset that emphasizes stimulant drive and intensifies the compulsive pull to redose.[22] Set and setting strongly modulate the experience, particularly the ratio between prosocial warmth and agitation.
In the only controlled head-to-head comparison, oral mephedrone 200 mg produced subjective effects comparable in quality to MDMA 100 mg — similar ratings of euphoria, well-being, and stimulation — but with earlier peak and substantially shorter total duration.[12] This rapid rise-and-fall is the feature most consistently linked to mephedrone's compulsive redosing pattern,[7] distinguishing it from MDMA's longer plateau and cocaine's qualitatively different character.
Effect Grid
At common doses, the full mephedrone experience is present: pronounced euphoria, strong stimulation, empathy enhancement and emotional warmth, marked sociability, and music enhancement. Thought acceleration is significant. Sexual arousal enhancement is frequently reported. Compulsive redosing urges typically emerge at this range.
Cardiovascular effects are substantial — elevated heart rate, increased blood pressure, pupillary dilation, and diaphoresis. Bruxism and jaw clenching become pronounced. Appetite is fully suppressed. Body temperature regulation may be affected, particularly in warm environments.
The experience lasts 3–5 hours orally. Sleep is impossible during effects and difficult for 1–2 hours after. The strong urge to redose is a defining feature of this dose range.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Tinnitus · Visual haze / noise · Olfactory hallucination
Body high · Physical fatigue · Bruxism · Spontaneous body sensations · Dehydration sensation · Dry mouth · Insomnia · Pupil dilation · Restlessness · Tactile euphoria · Excessive sweating · Sexual arousal enhancement · Breathing alteration · Heart rate perception changes · Muscle tension · Respiratory stimulation · Temperature dysregulation · Tingling / electric sensations · Dizziness · Headache · Nasal congestion · Nausea · Trembling · Laughter fits · Motor control impairment · Nystagmus (eye wobbles) · Vibrations / buzzing · Vomiting · Increased urination · Brain zaps · Salivation · Seizure threshold reduction
Spontaneous body sensations · Dehydration sensation · Dry mouth · Insomnia · Pupil dilation · Restlessness · Tactile euphoria · Excessive sweating · Sexual arousal enhancement · Breathing alteration · Heart rate perception changes · Muscle tension · Respiratory stimulation · Tingling / electric sensations · Dizziness · Headache · Nasal congestion · Nausea · Trembling · Laughter fits · Motor control impairment · Nystagmus (eye wobbles) · Vibrations / buzzing · Vomiting · Increased urination · Brain zaps · Salivation · Seizure threshold reduction
Motivation suppression · Aesthetic enhancement · Openness enhancement · Motivation enhancement · Cognitive dysphoria · Cognitive flexibility · Cognitive impairment · Focus enhancement · Immersion enhancement · Information processing enhancement · Introspection enhancement · Language enhancement · Novelty enhancement · Pattern recognition enhancement · Thought connectivity · Analysis enhancement · Creativity enhancement · Humor enhancement · Thought deceleration · Confusion · Multiple thought streams · Thought disorganization · Thought loops
Cognitive dysphoria · Cognitive flexibility · Cognitive impairment · Focus enhancement · Immersion enhancement · Information processing enhancement · Introspection enhancement · Language enhancement · Novelty enhancement · Pattern recognition enhancement · Thought connectivity · Analysis enhancement · Creativity enhancement · Humor enhancement · Thought deceleration · Confusion · Multiple thought streams · Thought disorganization · Thought loops
Anxiety suppression · Irritability · Anhedonia · Anxiety · Dysphoria · Emotional lability · Simultaneous emotions · Mania
Anxiety · Dysphoria · Emotional lability · Simultaneous emotions
Communication enhancement · Sociability enhancement · Trust enhancement · Ego inflation · Emotional susceptibility · Flow state · Depersonalization · Derealization
Emotional susceptibility · Flow state · Depersonalization · Derealization
Timeline
First alerts emerge as mild stimulation and a subtle lift in mood. Pupils begin to dilate. The onset is faster than MDMA but slower than insufflation.
Stimulation builds rapidly. Euphoria, sociability, and empathogenic warmth increase noticeably. Heart rate and blood pressure rise.
Maximum intensity: pronounced euphoria, strong empathy enhancement, music enhancement, and thought acceleration. Cardiovascular effects are at their peak. Compulsive redosing urges are strongest during this phase.
Effects remain clearly present but begin to diminish from peak. Stimulation persists while entactogenic warmth gradually fades. The urge to redose is common as peak effects wane.
Effects taper toward baseline. Residual stimulation may persist. Mood begins to dip below baseline for some users.
Residual low mood, fatigue, and mild cognitive fog are common in the hours following the experience, particularly after higher doses or redosing. Sleep quality may be reduced.
⚠ Do not drive or operate machinery until after a full night of sleep, as residual stimulant impairment and fatigue may persist.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- MDMA · amphetamine · methamphetamine
Toxicity
Acute toxicity
No human lethal dose has been established for mephedrone.safety citation needed The acute toxicity presentation is a sympathomimetic toxidrome: rapid heart rate, elevated blood pressure, chest pain, sweating, agitation, dilated pupils, and — in severe cases — dangerous overheating.[33][34]
Serotonin syndrome has been documented from mephedrone alone at recreational doses — a 22-year-old male developed rapid heart rate, sweating, muscle rigidity, exaggerated reflexes, and dangerous overheating following mephedrone use, with recovery over 15 hours.[9] Co-administration with other serotonergic drugs is not required to trigger this syndrome.
Cardiovascular effects
Mephedrone produces dose-dependent increases in heart rate, blood pressure, and cardiac output.[8][35] These effects are driven by catecholamine release, not direct action on heart ion channels.[8]
Hot environments — nightclubs, raves, outdoor festivals — amplify both cardiovascular and temperature-related risks.[32]
Thermoregulation
In cooler environments, mephedrone tends toward lowering body temperature; in warm settings, the response shifts toward dangerous overheating.[32][30][31] Human overdose cases consistently present with overheating. This environment-dependent response makes the setting of use a direct risk factor.
Fatalities
The first published mephedrone-associated death involved concurrent heroin use; death was attributed to multiple-drug toxicity.[36] A UK forensic review found that 84% of mephedrone-detected cases involved co-use of other substances or alcohol.[14]
Many early media-attributed deaths involved other substances on analytical confirmation; only a small number had mephedrone confirmed as the sole causative agent.[37] Contemporary UK data identify mephedrone as a key substance in 21 chemsex-related fatalities between 2017 and 2022.[6]
Psychological risks
Paranoia, hallucinations, and anxiety are documented at high doses or after prolonged use.[38] Cathinone intoxication can present with acute psychiatric symptoms indistinguishable from primary psychosis in emergency settings.[39] No formal prevalence estimates exist; the evidence derives from case reports rather than prospective studies.
Tolerance & dependence
Mephedrone reliably maintains self-administration in animal models, with dose-dependent reinforcing properties confirmed across multiple procedures.[40][11] The R-enantiomer drives most of the reinforcing effect.[16] Brain stimulation reward studies confirm dose-dependent facilitation of reward.[26]
In human surveys, compulsive redosing and difficulty stopping during a session are widely reported,[7] with a subset of regular users describing dependence features. Self-reported dependence symptoms show notable liability compared to MDMA, cocaine, and ketamine in poly-drug user samples.[41]
Binge exposure produces persistent serotonin system deficits in animals,[11] with long-term changes in anxiety-related behavior.[28] No controlled human withdrawal or formal dependence studies have been published.
Drug interactions
Serotonergic drugs
Mephedrone's potent serotonin release creates substantial risk for serotonin syndrome when combined with SSRIs, SNRIs, MAOIs, tramadol, lithium, or triptans. Mephedrone alone can cause serotonin syndrome;[9] adding any serotonergic agent escalates the risk.
Co-administration with MDMA raises synaptic serotonin through convergent mechanisms — both are potent serotonin releasers.[18][1] This combination carries substantial serotonin syndrome risk.
MAOIs would be expected to dramatically potentiate and prolong mephedrone's effects with life-threatening consequences, given its mechanism of massive monoamine release.safety citation needed
Alcohol
The only controlled human interaction study found that mephedrone 200 mg combined with alcohol produced greater euphoria than either alone, while mephedrone masked alcohol's sedative effects — potentially leading to higher alcohol consumption.[13] Cardiovascular effects were amplified.
Opioids
A fatal combination of mephedrone and heroin documents the danger of combining stimulants with respiratory depressants.[36]
Transporter blockers (MDPV)
When the DAT is blocked by MDPV, mephedrone can still release monoamines via OCT3,[19] producing paradoxically potent and unpredictable stimulation.
Contraindications
CYP2D6 poor and intermediate metabolizers
Individuals with reduced CYP2D6 function accumulate higher mephedrone blood levels, creating pharmacogenomically determined toxicity risk at doses tolerated by others.[20] CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) can produce the same effect.
Cardiovascular disease
Pre-existing heart conditions are a contraindication based on mephedrone's reliable, dose-dependent cardiovascular stimulation.[8][35] No safe lower dose has been established for individuals with cardiac pathology.
Concurrent serotonergic medication
Any concurrent serotonergic drug elevates serotonin syndrome risk. Mephedrone alone causes serotonin syndrome at recreational doses.[9]
Hot environments
Warm ambient temperatures shift mephedrone's thermoregulatory effects toward dangerous overheating,[32] increasing heat-related injury risk in nightclubs and outdoor festivals.
Alcohol co-use
Alcohol amplifies cardiovascular effects and euphoria while masking sedation, increasing both acute medical risk and the likelihood of excessive consumption.[13]
Pregnancy
No published data exist on mephedrone's reproductive or developmental effects.safety citation needed
Harm Reduction[edit]
Forms & Identification
Mephedrone hydrochloride is typically encountered as a white to off-white crystalline powder, though quality varies enormously in unregulated supply. Reagent testing provides a presumptive identity check but cannot confirm purity or rule out all adulterants — because mephedrone's visual appearance is indistinguishable from many other cathinone powders, cross-referencing multiple reagent results is essential.
Quantitative testing (FTIR or laboratory analysis) is the only way to verify purity. The wide purity range in seized samples means dosing from an untested batch carries inherent unpredictability — start lower than intended if purity is unknown.
Guidelines
- Test every batch with at least two reagent kits before use; consider quantitative analysis if available
- Pre-measure individual doses; avoid dipping into a communal bag
- Set a firm redose limit before the session — the urge to continue is pharmacologically predictable
- Space redoses by at least 90 minutes to reduce cardiovascular strain
- Stay hydrated but avoid overhydration — sip water steadily rather than drinking large amounts
- Avoid hot, poorly ventilated environments; take regular breaks from dancing or physical activity
- Eat a light meal 2–3 hours before oral dosing to reduce nausea
- Have a sober companion present who can monitor for warning signs
- Keep the oral route as default — intranasal and intravenous routes intensify compulsive redosing
Set & Setting
Mephedrone's short duration and compulsive redosing profile make pre-session planning unusually important. Decide on a total dose and number of redoses before the session begins — once effects are active, the urge to take more is pharmacologically driven and difficult to override. A trusted companion who can hold supply and enforce agreed limits meaningfully reduces binge risk.
The thermoregulatory profile makes environment a direct safety variable. Cool, well-ventilated spaces reduce overheating risk; hot, crowded environments amplify it. Access to water and regular breaks from physical activity are not optional in warm settings.
Aftercare & integration. The mephedrone comedown is characterized by low mood, irritability, difficulty concentrating, and disrupted sleep — effects consistent with temporary monoamine depletion. These typically resolve within 24–72 hours.
Prioritize sleep: use a dark, cool room and avoid screens. Eat nutrient-dense meals even if appetite is suppressed. Gentle physical activity and hydration support recovery. Avoid compensating with additional stimulants or alcohol during the comedown period.
If low mood or anxiety persist beyond 72 hours, or if the urge to use again feels compulsive, consider speaking with a healthcare professional. Repeated binge patterns warrant honest self-assessment of use frequency and escalation.
Recovery & Support
Mephedrone's compulsive redosing profile means that problematic use patterns can develop without a person recognizing the transition from recreational to compulsive. Warning signs include using more than planned in a session, inability to keep supply without using it, escalating frequency of sessions, and neglecting responsibilities during or after use.
Support options include SMART Recovery, local drug counseling services, and harm reduction organizations that offer non-judgmental guidance. For those in chemsex contexts, specialized services address the specific overlap between sexual behavior and stimulant use. Reaching out early — before dependence is entrenched — is substantially more effective than waiting for crisis.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizure, loss of consciousness, body temperature hot to the touch through clothing, muscle rigidity with jerking movements (possible serotonin syndrome), severe confusion, or inability to communicate coherently. These indicate a medical emergency — not just discomfort.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Move the person to a cool, quiet area
- 3. Remove excess clothing and apply cool (not ice-cold) water to skin if overheating
- 4. Place in the recovery position if unconscious but breathing
- 5. Do not restrain the person unless they are in immediate danger of self-harm
- 6. Do not induce vomiting
What to tell the dispatcher: Name the substance (mephedrone / 4-MMC), the estimated amount and time of last dose, the route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Mephedrone is controlled in all major Western jurisdictions as of 2012. It was the first synthetic cathinone to trigger widespread international scheduling, with bans cascading from Israel (2007) through Scandinavia (2008), Western Europe (2010), and North America (2011–2012).[5]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | DEA emergency scheduling October 2011; permanent Schedule I under Synthetic Drug Abuse Prevention Act, July 9, 2012 |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled from April 16, 2010; criminal penalties for possession and supply |
| European Union | Criminal law measures (2010) | EU-wide measures adopted October 2010; individual member state implementation |
| Germany | Controlled (Narcotics Act) | Narcotics law amendment, January 22, 2010 |
| France | Narcotic | Added to narcotics list, June 2010 |
| Netherlands | Controlled | Controlled from March 2010 |
| Denmark | Controlled substance | December 15, 2008 — among first bans globally |
| Sweden | Controlled substance | December 15, 2008 — among first bans globally |
| Israel | Controlled | December 2007 — first national ban globally |
| Canada | Schedule I (CDSA) | Scheduled 2012 |
| Australia | Illegal for human consumption | Controlled under Therapeutic Goods Act; major seizures 2008 and 2010 |
Despite characterization as an "emerging" novel psychoactive substance in some regulatory frameworks, mephedrone has an extensive published literature exceeding 300 primary papers and has been a scheduled controlled substance in all major jurisdictions for over a decade.
references
- [1]
- [2] ^abcdSimmler LD, Buser TA, Donzelli M, et al. (2012) Pharmacological characterization of designer cathinones in vitro — British Journal of Pharmacology doi:10.1111/j.1476-5381.2012.02145.x
- [3]
- [4] ^abSchifano F, Albanese A, Fergus S, et al. (2011) Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues — Psychopharmacology doi:10.1007/s00213-010-2070-x
- [5]
- [6] ^abcTyler M, Ward L, Grosse S (2025) Chemsex-related deaths in the United Kingdom (2017-2022): A review of the Forensic Toxicology data — Forensic Science International doi:10.1016/j.forsciint.2025.112553